Primary hepatic carcinoma with inhibin positivity in a young male patient: a rare tumor previously only reported in females-case report and review of literature.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ analysis
Carcinoma
/ chemistry
Diagnosis, Differential
Disease Progression
Female
Genetic Variation
High-Throughput Nucleotide Sequencing
Humans
Immunohistochemistry
Inhibins
/ analysis
Liver Neoplasms
/ chemistry
Male
Predictive Value of Tests
Treatment Outcome
Inhibin positive
Primary hepatic carcinoma
RNA albumin ISH positive
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
18
02
2020
accepted:
03
06
2020
revised:
28
05
2020
pubmed:
14
6
2020
medline:
31
3
2021
entrez:
14
6
2020
Statut:
ppublish
Résumé
Primary hepatic carcinoma with inhibin positivity is a rare aggressive liver tumor with seven cases described. The tumor presents at a younger age than primary hepatic carcinoma with all cases being females. RNA albumin ISH positivity suggests the tumor to be a primary hepatic carcinoma. The tumor is different from hepatocellular carcinoma as well as intrahepatic cholangiocarcinoma because of its distinct morphology, lack of hepatocellular differentiation, strong inhibin staining, and lack of typical mutations. A 26-year-old male presented with a 20-cm liver mass. The tumor progressed on therapy with development of multiple lung metastasis. Currently, the patient is enrolled in phase II clinical trial utilizing nivolumab and ipilumumab. While the tumor has a female preponderance, it is not exclusively found in females. Additional studies are necessary to determine the cause of inhibin staining, driving molecular alterations, natural history of this rare tumor, and to come up with consensus nomenclature.
Identifiants
pubmed: 32533342
doi: 10.1007/s00428-020-02864-y
pii: 10.1007/s00428-020-02864-y
doi:
Substances chimiques
Biomarkers, Tumor
0
Inhibins
57285-09-3
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
605-610Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
pubmed: 30207593
pmcid: 30207593
Vrettou E, Hytiroglou P, Sikas N, Soultoyannis I, Goodman ZD (2005) Hepatic adenocarcinoma expressing inhibin in a young patient on oral contraceptives. Virchows Arch 446:560–565. https://doi.org/10.1007/s00428-005-1241-3
doi: 10.1007/s00428-005-1241-3
pubmed: 15815932
Braxton DR, Saxe D, Damjanov N, Stashek K, Shroff S, Morrissette JD, Tondon R, Furth EE (2017) Molecular and cytogenomic profiling of hepatic adenocarcinoma expressing inhibinA, a mimicker of neuroendocrine tumors: proposal to reclassify as “cholangioblastic variant of intrahepatic cholangiocarcinoma”. Hum Pathol 62:232–241. https://doi.org/10.1016/j.humpath.2017.02.001
doi: 10.1016/j.humpath.2017.02.001
pubmed: 28232156
Wen KW, Srivastava A, Joseph N, Saunders T, Kakar S (2019) “Sex Cord-Like” hepatic carcinoma: a rare variant of intrahepatic cholangiocarcinoma? Abstract 1537. Page 54. Laboratory Investigation. Volume 99, Supplement 1
Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CCY, Wong BH, Myint SS, Rajasegaran V, Heng HL, Gan A, Zang ZJ, Wu Y, Wu J, Lee MH, Huang DC, Ong P, Chan-on W, Cao Y, Qian CN, Lim KH, Ooi A, Dykema K, Furge K, Kukongviriyapan V, Sripa B, Wongkham C, Yongvanit P, Futreal PA, Bhudhisawasdi V, Rozen S, Tan P, Teh BT (2012) Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 44:690–693
doi: 10.1038/ng.2273
Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, Tran Van Nhieu J (2012) GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol. 56(1):184–191
doi: 10.1016/j.jhep.2011.07.018
Basturk O, Berger MF, Yamaguchi H, Adsay V, Askan G, Bhanot UK (2017) Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenoca. Mod Pathol. 30(12):1760–1772
doi: 10.1038/modpathol.2017.60
Wu J, Matthaei H, Maitra A, Wood MDMLD, Eshleman JR et al (2011) Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3:92ra66
doi: 10.1126/scitranslmed.3002543
Saâda-Bouzid E et al (2015) Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. Modern Pathology 28.11:1404
doi: 10.1038/modpathol.2015.96
Franchi A, Calzolari A, Zampi G (1998) Immunohistochemical detection of c-fos and c-Jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch 432(6):515–519
doi: 10.1007/s004280050199
Yokoyama Y, Sagara M, Sato S, Saito Y (1998) Value of glutathiones-transferase π and the oncogene products c-Jun, c-Fos, cH-Ras, and c-Myc as a prognostic indicator in endometrial carcinomas. Gynecol Oncol 68(3):280–287
doi: 10.1006/gyno.1998.4936
Gupta S et al (2015) Selective participation of c-Jun with Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis in tongue cancer. Scientific Reports 5:16811
doi: 10.1038/srep16811
Decaens T, Godard C, de Reyniès A, Rickman DS, Tronche F, Couty JP, Perret C, Colnot S (2008) Stabilization of β-catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology 47(1):247–258
doi: 10.1002/hep.21952
Clotman F, Jacquemin P, Plumb-Rudewiez N, Pierreux CE, van der Smissen P, Dietz HC, Courtoy PJ, Rousseau GG, Lemaigre FP (2005) Control of liver cell fate decision by a gradient of TGFβ signaling modulated by Onecut transcription factors. Genes Dev 19(16):1849–1854
doi: 10.1101/gad.340305
Rodgarkia-Dara C, Vejda S, Erlach N, Losert A, Bursch W, Berger W, Schulte-Hermann R, Grusch M (2006) The activin axis in liver biology and disease. Mutation Research/Reviews in Mutation Research 613(2–3):123–137
doi: 10.1016/j.mrrev.2006.07.002
Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, el-Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB, Abou-Alfa GK (2018) Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res 24:4154–4161. https://doi.org/10.1158/1078-0432.ccr-18-0078
doi: 10.1158/1078-0432.ccr-18-0078
pubmed: 29848569
pmcid: 6642361
Churi CR, Shroff R, Wang Y, Rashid A, Kang HSC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9:e115383. https://doi.org/10.1371/journal.pone.0115383
doi: 10.1371/journal.pone.0115383
pubmed: 25536104
pmcid: 4275227
Frost K, Seir K, Lackner A, Grusch M, Grasl-Kraupp B, Schulte-Hermann R, Rodgarkia-Dara C (2011) Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma? Br J Cancer 104(8):1303–1312
doi: 10.1038/bjc.2011.53
Nasir A, Lehrke HD, Mounajjed T, Said S, Zhang L, Yasir S, Shah SS, Chandan VS, Smyrk TC, Moreira RK, Boland Froemming JM, Herrera Hernandez LP, Wu T-T, Graham RP (2019) Albumin in situ hybridization can be positive in adenocarcinomas and other tumors from diverse sites. Am J Clin Pathol 152(2):190–199
doi: 10.1093/ajcp/aqz032